Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies [solid tumours].

Next Previous
Trial Profile

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies [solid tumours].

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Temsirolimus (Primary)
  • Indications Colon cancer; Duodenal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Intestinal cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Pharyngeal neoplasms; Rectal cancer; Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 01 Sep 2021 Results published in the American Journal of Clinical Oncology
  • 22 Jun 2012 Actual patients number is 26 as reported by ClinicalTrials.gov.
  • 22 Jun 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top